To further elucidate the potential of the BATF and EGR1 gene expression levels as prognostic biomarkers for AML patients undergoing allo-HSCT, we conducted an in-depth analysis of a cohort of allo-HSCT recipients. The gene discussed is EGR1; the disease is acute myeloid leukemia.